Работы, цитирующие эту работу

Работ: 2

Работа: Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma

1. The Role of CD56 as an Immunophenotypic Marker in the Clinical Course of Multiple Myeloma

   Azat Karabekov, Vadim Kemaikin, Zhandos Burkitbayev +15

   СтатьяMultiple Myeloma Research and TreatmentsJournal of Clinical Medicine2026Цитирований: 0

   ABIABI:AkademIndex/openalex/2026.article.015051

2. Advances in monitoring and therapy from minimal residual disease to CAR-T cells in multiple myeloma and precursor disorders

   Amr Ali Mohamed Abdelgawwad El‐Sehrawy, Ghaleb Oriquat, Sokhib Saidov +5

   СтатьяCAR-T cell therapy researchClinica Chimica Acta2026Цитирований: 0

   ABIABI:AkademIndex/openalex/2026.article.017391